OCT 27, 2020 8:00 AM PDT

A Super Sensitive Alzheimer's Test Powered by Nanozymes

WRITTEN BY: Tara Fernandez

Simple tasks are now uphill struggles, social situations aren’t fun, and the house keys are missing again. By the time these symptoms of Alzheimer’s disease begin to take a toll on a patient’s quality of life, the damage is done — there is already severe neurodegeneration. 

Scientists at Washington State University (WSU) have revealed a diagnostic innovation for Alzheimer’s that is 10 times more powerful than existing technologies, which could make it possible for doctors to detect the onset of the disease much earlier.

Existing diagnostic methods rely heavily on brain imaging technologies such as magnetic resonance imaging, or MRI, and CT scans. Here, physicians are looking for structural changes in the neuroanatomy, particularly shrinkage in the temporal and parietal lobes of the brain. Another (more painful) option is to take a sample of spinal fluid and analyze it for the presence of beta-amyloid biomarkers.

The team at WSU has developed a single-atom nanozyme: a synthetic enzyme that detects the presence of Alzheimer’s biomarkers with unprecedented sensitivity. These nanostructures, composed of carbon nanotubes coated with iron atoms, can detect trace amounts of beta-amyloid proteins, at levels 10 times lower than if conventional enzyme-linked immunosorbent assays (ELISA) were used. With this level of sensitivity, Alzheimer’s biomarkers could be picked up in blood samples from patients without the need for spinal taps.

“The nanozyme based on a single-atom catalyst that we created has a similar structure as a natural enzyme with remarkable enzyme-like activity and paved the way for detecting the Alzheimer’s Disease biomarker,” said Professor Dan (Annie) Du from WSU’s School of Mechanical and Materials Engineering who led the study. These novel molecules are also superior to ELISAs that use naturally-derived enzymes in that they are more cost-effective and have a much longer shelf life.

The team plans to continue the study by validating the newly-developed assay using blood samples from Alzheimer’s patients and healthy controls.

“This shows great potential for the early-stage diagnosis of Alzheimer’s Disease,” commented Du. 

Sources: Washington State University, Research.


 

About the Author
  • Tara Fernandez has a PhD in Cell Biology and has spent over a decade uncovering the molecular basis of diseases ranging from skin cancer to obesity and diabetes. She currently works on developing and marketing disruptive new technologies in the biotechnology industry. Her areas of interest include innovation in molecular diagnostics, cell therapies, and immunology. She actively participates in various science communication and public engagement initiatives to promote STEM in the community.
You May Also Like
NOV 18, 2020
Genetics & Genomics
Choosing an NGS workflow: What are you looking for?
NOV 18, 2020
Choosing an NGS workflow: What are you looking for?
  It’s easy to be overwhelmed by the number of workflows that are available for NGS. How do you choose? While ...
JAN 14, 2021
Clinical & Molecular DX
Tip of the Iceberg: Inaccuracies in Prostate Cancer Diagnostics
JAN 14, 2021
Tip of the Iceberg: Inaccuracies in Prostate Cancer Diagnostics
  Only 10 percent of icebergs are visible on the surface of the water; the remaining 90 percent remains submerged. ...
JAN 13, 2021
Clinical & Molecular DX
E-Stethoscope Picks up Good (and Bad) Vibrations
JAN 13, 2021
E-Stethoscope Picks up Good (and Bad) Vibrations
A medical device used to survey lung sounds to monitor for signs of respiratory distress has received FDA clearance. RES ...
FEB 02, 2021
Clinical & Molecular DX
Keeping an Eye on COVID Clusters With Rapid Sequencing
FEB 02, 2021
Keeping an Eye on COVID Clusters With Rapid Sequencing
Contact tracing is a powerful tool used by public health authorities to help slow the spread of infectious diseases such ...
FEB 15, 2021
Clinical & Molecular DX
Asking Patients the Right Questions About Their Symptoms
FEB 15, 2021
Asking Patients the Right Questions About Their Symptoms
A patient is admitted to the hospital after experiencing chest pains. What are the right questions that hospital staff a ...
MAR 02, 2021
Clinical & Molecular DX
Test Before You Travel: Tiny Smartphone Device Checks for COVID in 60 Minutes
MAR 02, 2021
Test Before You Travel: Tiny Smartphone Device Checks for COVID in 60 Minutes
According to the CDC’s latest travel regulations, all air passengers must have a negative COVID test before boardi ...
Loading Comments...